BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34430406)

  • 1. Comprehensive data analysis of genomics, epigenomics, and transcriptomics to identify specific biomolecular markers for prostate adenocarcinoma.
    Ye C; Wang H; Li Z; Xia C; Yuan S; Yan R; Yang X; Ma T; Wen X; Yang D
    Transl Androl Urol; 2021 Jul; 10(7):3030-3045. PubMed ID: 34430406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of prognostic markers in sarcomas base on a multi-omics analysis.
    Song Y; Yang K; Sun T; Tang R
    BMC Med Genomics; 2021 Jan; 14(1):31. PubMed ID: 33509178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    Zhao Y; Gao Y; Xu X; Zhou J; Wang H
    BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma.
    Xu Y; She Y; Li Y; Li H; Jia Z; Jiang G; Liang L; Duan L
    Biomed Pharmacother; 2020 May; 125():109859. PubMed ID: 32036209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
    Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
    Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated multi-omics analysis of genomics, epigenomics, and transcriptomics in ovarian carcinoma.
    Zheng M; Hu Y; Gou R; Wang J; Nie X; Li X; Liu Q; Liu J; Lin B
    Aging (Albany NY); 2019 Jun; 11(12):4198-4215. PubMed ID: 31257224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Genomic and Epigenomic Analyses on Transcriptomic Regulation in Stomach Adenocarcinoma.
    Chen J; Liu W; Du J; Wang P; Wang J; Ye K
    Front Genet; 2021; 12():778095. PubMed ID: 35222516
    [No Abstract]   [Full Text] [Related]  

  • 8. A N
    Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
    J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenomic and genomic analysis of transcriptome modulation in skin cutaneous melanoma.
    Chen W; Cheng P; Jiang J; Ren Y; Wu D; Xue D
    Aging (Albany NY); 2020 Jul; 12(13):12703-12725. PubMed ID: 32639949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
    Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
    Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
    Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
    Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis of genomic, epigenomic and transcriptomic data identified molecular subtypes of esophageal carcinoma.
    Ma M; Chen Y; Chong X; Jiang F; Gao J; Shen L; Zhang C
    Aging (Albany NY); 2021 Feb; 13(5):6999-7019. PubMed ID: 33638948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer.
    Kong L; Liu P; Zheng M; Xue B; Liang K; Tan X
    Epigenomics; 2020 Mar; 12(6):507-524. PubMed ID: 32048534
    [No Abstract]   [Full Text] [Related]  

  • 14. A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
    Wang X; Zhou B; Xia Y; Zuo J; Liu Y; Bi X; Luo X; Zhang C
    BMC Cancer; 2021 Jul; 21(1):801. PubMed ID: 34247575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.
    Piao S; Zheng L; Zheng H; Zhou M; Feng Q; Zhou S; Ke M; Yang H; Wang X
    J Immunol Res; 2022; 2022():2922832. PubMed ID: 35707002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Analysis of Multiomics Data Identified Molecular Subtypes and Oxidative Stress-Related Prognostic Biomarkers in Glioblastoma Multiforme.
    Ma Y; Xi Z
    Oxid Med Cell Longev; 2022; 2022():9993319. PubMed ID: 36193073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma.
    Ye C; Qin S; Qiu S; Zhao L; Miao J; Chen Y; Zhou T
    Transl Androl Urol; 2022 Dec; 11(12):1691-1705. PubMed ID: 36632155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.
    Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
    Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
    Fei H; Chen X
    Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.